ClinicalTrials.gg
CompletedNCT06004050Updated Sep 25, 2025

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

A Phase 3 interventional study of Delgocitinib and Vehicle cream in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 37 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Primary conditionEczemaRegistry: Skin DiseasesReclassifiedWhy we changed it
Registry
Skin Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Eczema
Why
  1. The study's listed conditions name Eczema, a narrower term within Skin Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
362
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
5th of 12
362 · median 178
Started
2023
the only one that year
Phase 3
7 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 7 in phase 3, and was the 12th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema (CHE).

Read the detailed description

The trial comprises of a 16-week double-blind, treatment period, followed by an open label treatment period of 36 weeks. In the double-blind treatment period two thirds of participants will be randomly assigned to receive delgocitinib and one third will receive placebo/vehicle. In the double-blind treatment period, participants will use delgocitinib twice a day. In the open label period, participants will only use delgocitinib when needed (if their CHE flares up). Some participants will also give blood samples at the start of the trial for pharmacokinetic measurements. Participants will visit the clinic every 4 weeks.

03

Conditions studied

  • Chronic Hand Eczema

Browse trials for

Keywords

  • Dermatologic Disease
  • Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Delgocitinib
04

In context

Eczema Reclassified

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

This study's enrollment of 362 is above the median of 91 across 403 interventional studies indexed under Eczema.

Browse Eczema studies →

Lead sponsor

LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.

Compared within Eczema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or above at screening for adult participants and age 12-17 years at screening and baseline for adolescent participants.
  2. Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months. Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4).
  3. HESD itch score (weekly average) of ≥4 points at baseline. The baseline weekly average will be calculated from daily assessments of itch severity during the 7 days immediately preceding the baseline visit (Day -7 to Day -1). A minimum of 4 itch scores out of the 7 days is required to calculate the baseline average score.
  4. Participants who have a documented recent history of inadequate response to treatment with topical (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).

    • Inadequate response is defined as a history of failure to achieve and maintain a low disease activity state (comparable to an IGACHE score of ≤2) despite treatment with a daily regimen of TCS of class III-IV (potent to very potent), applied for at least 28 days or for the maximum duration recommended by the product prescribing information, whichever is shorter.
    • Important side effects or safety risks are those that outweigh the potential treatment benefits and include intolerance to treatment, reactions, and significant skin atrophy as assessed by the physician.
  5. Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.
  6. A woman of (WOCBP) must use an acceptable method of throughout the trial up until the last application of medicinal product (IMP).

Exclusion criteria

Exclusion Criteria:

  1. Active atopic dermatitis (AD) requiring medical treatment in regions other than the hands and feet.
  2. Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
  3. infection (e.g. impetiginized hand eczema) on the hands.
  4. Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the medicinal product (IMP), or reduce the participant's ability to participate in the trial. Clinically significant infections are defined as:

    • A systemic infection.
    • A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
  5. History of any known primary immunodeficiency disorder including a positive (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
  6. History of cancer:

    • Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to screening.
    • Participants who have had other are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to screening.
  7. Any disorder which is not stable and could:

    • Affect the safety of the participant throughout the trial.
    • Impede the participant's ability to complete the trial. Examples include but are not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, immunological, and psychiatric disorders, and major physical impairment.
  8. Any abnormal finding which may:

    • Put the participant at risk because of their participation in the trial.
    • Influence the participant's ability to complete the trial. The abnormal finding must be clinically significant and observed during the screening period. Examples include abnormal findings in physical examination, vital signs, , hematology, clinical chemistry, or urinalysis.
  9. Positive surface antigen or virus antibody serology at screening.
  10. (ALT) or aspartate aminotransferase (AST) level ≥2.0× at screening.
  11. Known or suspected to any component(s) of the IMP.
  12. Systemic treatment with drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), traditional Chinese medicines (TCMs) (including herbals), or within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).
  13. Use of tanning beds, phototherapy (e.g. UVB, UVA1, PUVA), or bleach baths on the handswithin 28 days prior to baseline.
  14. Previous or current treatment with Janus Kinase (JAK) inhibitors (including delgocitinib/LEO 124249),systemic or topical.
  15. Cutaneously applied treatment with immunomodulators (e.g. PDE-4 inhibitors, pimecrolimus, tacrolimus), TCMs (including herbals), or TCS on the hands within 14 days prior to baseline.
  16. Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
  17. Other transdermal or cutaneously applied therapy on the hands (except for the use of participant's own emollients) within 7 days prior to baseline.
  18. Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
  19. Treatment with any marketed biological therapy or investigational biologic agents (including immunoglobulin, anti-IgE, and dupilumab):

    • Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
    • Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
  20. Treatment with any non-marketed drug substance (that is, an agent that has not yet been made available for clinical use following registration) within the last 28 days prior to baseline or 5 half-lives, whichever is longer.
  21. Major surgery within 8 weeks prior to screening, or planned in-patient surgery or hospitalization during the trial period.
  22. Current participation in any other interventional clinical trial.
  23. Previously randomized in this clinical trial.
  24. Concurrent skin diseases on the hands, e.g. tinea manuum.
  25. Active psoriasis on any part of the body.
  26. Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.
  27. Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.
  28. Participants who are legally institutionalized.
  29. Women who are pregnant or lactating.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
362 participants (actual)

Study arms

  • Experimental
    Double-Blind Period: Twice-Daily Delgocitinib Cream

    20 mg/g twice daily

    Drug: Delgocitinib

  • Placebo comparator
    Double-Blind Period: Twice-Daily Vehicle Cream

    20 mg/g twice daily

    Other: Vehicle cream

  • Experimental
    Open Label Period: Twice-Daily Delgocitinib

    20 mg/g twice daily

    Drug: Delgocitinib

Interventions

  • Topical administration

  • OtherVehicle cream

    Topical administration

07

What researchers measure

Primary outcomes

  1. Investigator Global Assessment for Chronic Hand Eczema Score (IGA-CHE TS) at Week 16

    The IGA-CHE score ranges from 0 (clear) to 4 (severe). Treatment response is defined as a score of 0 or 1.

    Time frame: Week 16

Secondary outcomes

  1. Hand Eczema Severity Index (HECSI)-90 at Week 16

    Defined as at least a 90% improvement in HECSI score from baseline.

    Time frame: Week 16

  2. HECSI-75 at Week 16

    Defined as at least a 75% improvement in HECSI score from baseline.

    Time frame: Week 16

  3. Percentage Change in HECSI Score From Baseline to Week 16

    HECSI score is used to rate the severity of hand eczema and ranges from 0 (lowest possible score) to 360 (highest possible score).

    Time frame: Baseline and Week 16

  4. Number of Participants With Reduction of Hand Eczema Symptom Diary (HESD) Itch Score by ≥4 Points From Baseline at Week 16

    Time frame: Baseline and Week 16

  5. Number of Participants With Reduction of HESD Score by ≥4 Points From Baseline at Week 16

    Time frame: Baseline and Week 16

  6. Number of Participants With Reduction of HESD Pain Score by ≥4 Points From Baseline at Week 16

    Time frame: Baseline and Week 16

  7. Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16

    Time frame: Baseline and Week 16

  8. Change in HESD Score From Baseline to Week 16

    Time frame: Baseline and Week 16

  9. Change in HESD Itch Score From Baseline to Week 16

    Time frame: Baseline and Week 16

  10. Change in HESD Pain Score From Baseline to Week 16

    Time frame: Baseline and Week 16

  11. Change in Hand Eczema Impact Scale (HEIS) Score

    Time frame: Baseline and Week 16

  12. Change in HEIS Proximal Daily Activity Limitations (PDAL) Score

    Time frame: Baseline and Week 16

  13. Number of Participants With Reduction of DLQI Score of ≥4 Points From Baseline at Week 16

    Time frame: Baseline and Week 16

  14. Number of Treatment-Emergent Adverse Events (AEs)

    Time frame: From baseline to Week 16

  15. Number of Treatment-Emergent AEs

    Time frame: From Week 16 to Week 54

  16. Area Under the Curve (AUC 0-12)

    Time frame: Day 1 and Day 8 post-dose

  17. Maximum Serum Concentration (Cmax)

    Time frame: Day 1 and Day 8 (0-12 hours post-dose)

  18. Time to Peak Drug Concentration (Tmax)

    Time frame: Day 1 and Day 8 (0-12 hours post-dose)

08

Study locations

37 sites
  • LEO Pharma Investigational Site
    Beijing, 100044, China
  • LEO Pharma Investigational Site
    Beijing, 100050, China
  • LEO Pharma Investigational Site
    Beijing, 100080, China
  • LEO Pharma Investigational Site
    Beijing, 100730, China
  • LEO Pharma Investigational Site
    Changchun, 130021, China
  • LEO Pharma Investigational Site
    Changsha, 410008, China
  • LEO Pharma Investigational Site
    Changsha, 410011, China
  • LEO Pharma Investigational Site
    Changzhou, 213000, China
  • LEO Pharma Investigational Site
    Chengdu, 610021, China
  • LEO Pharma Investigational Site
    Chengdu, 610044, China
  • LEO Pharma Investigational Site
    Fuzhou, 350005, China
  • LEO Pharma Investigational Site
    Guangzhou, 510030, China
  • LEO Pharma Investigational Site
    Guangzhou, 510260, China
  • LEO Pharma Investigational Site
    Guiyang, 550004, China
  • LEO Pharma Investigational Site
    Hangzhou, 310003, China
  • LEO Pharma Investigational Site
    Hangzhou, 310006, China
  • LEO Pharma Investigational Site
    Hangzhou, 310014, China
  • LEO Pharma Investigational Site
    Hefei, 230601, China
  • LEO Pharma Investigational Site
    Nanchang, 330200, China
  • LEO Pharma Investigational Site
    Nanjing, 210003, China
  • LEO Pharma Investigational Site
    Nanyang, 473112, China
  • LEO Pharma Investigational Site
    Shanghai, 200443, China
  • LEO Pharma Investigational Site
    Shenyang, 110002, China
  • LEO Pharma Investigational Site
    Shenzhen, 518020, China
  • LEO Pharma Investigational Site
    Shenzhen, 518033, China
  • LEO Pharma Investigational Site
    Shenzhen, 518052, China
  • LEO Pharma Investigational Site
    Shenzhen, 518058, China
  • LEO Pharma Investigational Site
    Shijiazhuang, 050030, China
  • LEO Pharma Investigational Site
    Wenzhou, 325000, China
  • LEO Pharma Investigational Site
    Wuhan, 430023, China
  • LEO Pharma Investigational Site
    Wuhan, 430030, China
  • LEO Pharma Investigational Site
    Wuhan, 430071, China
  • LEO Pharma Investigational Site
    Wuxi, 214043, China
  • LEO Pharma Investigational Site
    Xianyang, 712000, China
  • LEO Pharma Investigational Site
    Yinchuan, 750003, China
  • LEO Pharma Investigational Site
    Yiwu, 322000, China
  • LEO Pharma Investigational Site
    Zhenjiang, 212000, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2024, 15 months.

Of 66 industry-sponsored phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 71 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Aug 22, 2023
StartActual
Sep 5, 2023
Primary completionActual
Dec 16, 2024
CompletionActual
Sep 12, 2025
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06004050
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Sep 5, 2023
Primary completion
Dec 16, 2024
Completion
Sep 12, 2025
Last update
Sep 25, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion